1. The test results will be used to make a clinical management decision; AND 2. At least ONE (1) of the following medical criteria is met for APC genetic testing, as specified below in items a through g:
a. Member has a personal history of 10 or more adenomas (adenomatous polyps); OR ∞ ∞ Note: The National Comprehensive Cancer Network (NCCN) guidelines recommend comprehensive genetic testing (i.e., genetic testing for FAP, AFAP, and MAP) when a member presents with a known deleterious APC mutation in the family or a personal history of 20 or more cumulative adenomas. The Plan considers comprehensive testing medically necessary, as specified in this NCCN guideline.
b. Member has a personal history of desmoid tumor; OR c. Member has a personal history of hepatoblastoma; OR d. Member has a personal history of cribriform-morular variant of papillary thyroid cancer; OR e. Member has a personal history of multifocal, bilateral congenital hypertrophy of the retinal pigment epithelium (CHRPE), a pigmented fundus lesion of the retina associated with FAP; OR f. For predictive testing in a high-risk member who is a first-degree relative (i.e., full biological sibling, biological parent, or biological child) of an affected individual and/or proband with a disease causing mutation for FAP or AFAP and/or a known APC mutation; OR ∞ ¤ ∞ Note: The National Comprehensive Cancer Network (NCCN) guidelines recommend comprehensive genetic testing (i.e., genetic testing for FAP, AFAP, and MAP) when a member presents with a known deleterious APC mutation in the family or a personal history of 20 or more cumulative adenomas. The Plan considers comprehensive testing medically necessary, as specified in the Genetic/Familial High-Risk Assessment NCCN guidelines.
Genetic Testing for Hereditary Colorectal Cancer + Plan refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states und er the trade name Well Sense Health Plan.
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¤ Note: According to NCCN recommendations included in the Genetic/Familial High-Risk Assessment: Colorectal guidelines, Version 1.2018 -July 12, 2018, FAP genetic testing in children should be done by age 10 when colon screening would be initiated. In select cases where hepatoblastoma screening will be pursued, FAP genetic testing could be done in infancy.
g. Member has a differential diagnosis of AFAP vs. MAP vs. Lynch syndrome (with the order of testing for APC mutations or MMR mutations determined by clinical presentation, as determined by the treating specialist).
B. MUTYH Gene Mutation Testing Associated with MUTYH-Associated Polyposis (MAP):
MUTYH-associated polyposis (MAP) is caused by mutations in the MUTYH gene. According to NCCN guidelines, MUTYH genetic testing is NOT indicated for a personal history of a desmoid tumor, hepatoblastoma, cribriform-morular variant of papillary thyroid cancer, or multifocal/bilateral CHRPE. When APC mutation testing is negative, MUTYH genetic testing may be medically necessary when applicable Plan criteria are met. The order of testing for APC and MUTYH genetic testing is at the discretion of the treating provider.
BOTH of the following applicable criteria must be met for the evaluation of MUTYH gene mutations associated with MAP, as specified below in item 1 and item 2:
1. The test results will be used to make a clinical management decision; AND 2. At least ONE (1) of the following medical criteria is met, as specified below in items a through c:
a. Member has a personal history of 10 or more adenomas (adenomatous polyps); OR ∞ ∞ Note: The National Comprehensive Cancer Network (NCCN) guidelines recommend comprehensive genetic testing (i.e., genetic testing for FAP, AFAP, and MAP) when a member presents with a known deleterious APC mutation in the family or a personal history of 20 or more cumulative adenomas. The Plan considers comprehensive testing medically necessary, as specified in the Genetic/Familial High-Risk Assessment NCCN guidelines.
b. For predictive testing in a high-risk member age 18 or older who is a first-degree relative (i.e., full biological sibling, biological parent, or biological child) of an affected individual and/or proband with a known deleterious MUTYH mutation and findings are consistent with recessive inheritance; OR ∞ ∞ Note: The National Comprehensive Cancer Network (NCCN) guidelines recommend comprehensive genetic testing (i.e., genetic testing for FAP, AFAP, and MAP) when a 6 of 38 member presents with a known deleterious APC mutation in the family or a personal history of 20 or more cumulative adenomas. The Plan considers comprehensive testing medically necessary, as specified in the Genetic/Familial High-Risk Assessment NCCN guidelines.
c. The member has a personal history of serrated polyposis syndrome and meets at least ONE (1) of the following criteria, as specified below in items (1) through (3):
(1) Personal history of at least five (5) serrated polyps (which may include hyperplastic polyps, sessile serrated adenomas/polyps, and/or traditional serrated adenomas) proximal to the sigmoid colon with two (2) or more of these being larger than 10 mm in size; OR
(2) Personal history of any number of serrated polyps (which may include hyperplastic polyps, sessile serrated adenomas/polyps, and/or traditional serrated adenomas) proximal to the sigmoid colon in a member who has a first-degree relative (i.e., full biological sibling, biological parent, or biological child) with serrated polyposis; OR
(3) Personal history of 20 or more serrated polyps (which may include hyperplastic polyps, sessile serrated adenomas/polyps, and/or traditional serrated adenomas) of any size distributed throughout the colon.□ □ Note: For this criterion, distal polyps localized to the rectum and sigmoid are excluded UNLESS the polyps are greater than 10 mm in size and/or display additional characteristics of serrated polyps (i.e., serrations extending to the base of crypt, with widened or boot-shaped crypt base).
II. Genetic Testing for Lynch Syndrome (Previously Termed Hereditary Nonpolyposis Colorectal Cancer or HNPCC):
There are different approaches to evaluation of Lynch syndrome: Genetic testing of sequence variants (including reflex testing for large genomic rearrangements) in high-risk and affected members, microsatellite instability (MSI) of tumor tissue, and immunohistochemistry (IHC) of tumor tissue. As stated in the Limitations section of this policy, Plan Medical Director review and approval are required for the use of multigene panels to diagnosis of Lynch syndrome when used as an alternative to targeted, syndrome-specific genetic testing or when tumor tissue is not available or insufficient for genetic testing. The following applicable criteria must be met for genetic testing for Lynch syndrome, as specified below in item A for blood-based genetic testing to evaluate mismatch repair mechanism (MMR) genes, item B for genetic testing of tumor tissue with immunohistochemistry (IHC) and microsatellite instability (MSI), and/or item C for genetic testing for EPCAM gene variant testing (using blood-based genetic testing or testing of tumor tissue).
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A. Criteria for Blood-Based Genetic Testing to Evaluate MMR Genes (i.e., MLH1, MSH2, MSH6, and PMS2) to Diagnose Lynch Syndrome:
Deleterious mutations in any of the four (4) mismatch repair mechanism (MMR) genes (i.e., MLH1, MSH2, MSH6, and PMS2) or EPCAM (not a mismatch repair gene) are diagnostic for Lynch syndrome. See criteria in item C (Criteria for Genetic Testing of EPCAM Gene to Diagnose Lynch Syndrome Using Tumor Tissue or Blood-Based Testing) rather than this section for guidelines related to EPCAM testing.
Blood-based genetic testing of the MMR genes MLH1, MSH2, MSH6, and PMS2 is considered medically necessary for at least ONE (1) of the following indications when applicable Plan criteria are met: (1) Predictive genetic testing for a high-risk member;
(2) genetic testing of affected member when no tumor tissue is available or there is an insufficient tumor sample; or (3) when the treating provider has determined that blood-based MMR germline mutation testing is medically necessary in addition to genetic testing of tumor tissue to make a definitive diagnosis of Lynch syndrome. BOTH of the following criteria must be met for blood-based genetic testing of the MMR genes (i.e., MLH1, MSH2, MSH6, and PMS2) to diagnose Lynch syndrome, as specified below in item 1 and item 2:
1. The test results will be used to make a clinical management decision; AND 2. At least ONE (1) of the following medical criteria is met, as specified below in items a through e: a. The member is diagnosed with endometrial cancer before 50 years of age (for the diagnosis of Lynch syndrome); OR b. The member is diagnosed with colorectal cancer before 50 years of age (for the diagnosis of Lynch syndrome); OR c. EITHER the Amsterdam II criteria or the Revised Bethesda guidelines are met for a member age 18 or older on the date of testing (including an unaffected member when applicable family history criteria are met or a member with endometrial cancer or colorectal cancer according to the applicable age criterion for testing), as specified below in item (1) for Amsterdam II criteria or item (2) revised Bethesda guidelines:
(1) Amsterdam II Criteria:
Member has three (3) or more biological relatives who have had cancer associated with Lynch syndrome** or documented Lynch syndrome and ALL of the following criteria related to family medical history must be present, as specified below in items (a) through (e): (1) A first-degree relative or second-degree relative of a member satisfying the Amsterdam II criteria or Revised Bethesda guidelines (as specified above); OR
(2) A first-degree or second-degree relative of a member with a known MMR mutation or EPCAM mutation for Lynch syndrome; OR
(3) The treating provider has determined the member's predicted risk of Lynch syndrome is greater than five (5) percent using at least ONE (1) of the following prediction models (as defined in the Definitions section of this policy), as specified below in items (a) through ( 
EPCAM gene mutation testing (using EPCAM molecular testing in tumor tissue or blood-based EPCAM variant testing) is considered medically necessary when BOTH of the following criteria are met, as specified below in item 1 and item 2:
a. EPCAM genetic testing for a member with colorectal cancer, for the diagnosis of Lynch syndrome, when at least ONE (1) of the following criteria are met, as specified below in items (1) through (3):
(1) Tumor tissue shows lack of MSH2 expression by immunohistochemistry (IHC) and member is negative for a germ line mutation in MSH2; OR
(2) Tumor tissue with the microsatellite instability-high (MSI-H) histology and the member is negative for a germ line mutation in MLH1, MSH2, MSH6, and PMS2 genes; OR
(3) The treating provider will conduct testing of all four (4) MMR genes (i.e., MLH1, MSH2, MSH6, and PMS2 genes) and EPCAM gene concurrently (RATHER than sequentially); OR b. At-risk relative (who is a member age 18 or older) of an individual with Lynch syndrome with a known EPCAM mutation; OR c. Member age 18 or older on the date of testing without colorectal cancer but with a family history meeting the Amsterdam II criteria or Revised Bethesda guidelines, when no affected family members have been tested for mismatch repair mechanism (MMR) mutations, and when sequencing for MMR mutations is negative.
Limitations
1. The use of Septin 9 (SEPT9) methylation testing for colorectal cancer is considered experimental and investigational due to insufficient studies that document the clinical utility of this type of test to detect colorectal cancer. Using DNA extraction from patient plasma, the Septin 9 (SEPT9) methylation assay is based on the finding that there is a significant difference in SEPT9 methylation between individuals with colorectal cancer and those with normal colorectal tissue. Examples of this type of testing include but are not limited to the following:
ColoVantage™ -Methylated Septin 9 (Quest Diagnostics Inc.), Epi proColon (Epigenomics Inc.), Septin 9 (SEPT9) -Methylated DNA Detection by Real-Time PCR (ARUP Laboratories).
2. The Plan considers disease-targeted ATM, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A (p16INK4A/p14ARF), CHEK2, MSH2, NBN, PALB2, PTEN, RAD51C, RAD51D, SMAD4, STK11, and/or TP53 genes or testing of these genes using multi-gene panels (e.g., myRisk Hereditary Cancer by Myriad Genetic Laboratories, Inc.) to determine susceptibility to hereditary colorectal cancer to be experimental and investigational due to insufficient clinical utility of testing. Any genetic testing that does NOT meet the applicable medical necessity criteria specified in the Medical Policy Statement section of this policy requires Plan Medical Director review.
3. Genetic testing that is marketed directly to consumers (direct-to-consumer or DTC) that are ordered by a member without the order of a treating health care provider is not covered.
4.
A request for genetic testing of a member before the applicable minimum age criterion (i.e., minimum age of 18 for MAP predictive testing and minimum age of 18 for Lynch syndrome predictive testing) for an at-risk member who otherwise meets applicable medical necessity criteria will require Plan Medical Director review for individual consideration based on the member's personal medical history, family medical history and supports, treatment plan based on test results, and clinical indications for testing. The National Society of Genetic Counselors (NSGC) "encourages deferring predictive genetic testing of minors for adult-onset conditions when results will not impact childhood medical management or significantly benefit the child." The use of a multigene testing panel is generally considered to NOT be medically necessary as an alternative to, or in addition to, disease-specific genetic testing to predict the susceptibility to hereditary colorectal cancer due to limited data on clinical validity and clinical utility of multigene testing. If the treating provider is recommending multigene panel testing rather than, or in addition to, the condition-targeted genetic testing, Plan Medical Director review is required. For multigene panel testing to be considered medically necessary, medical record documentation must be submitted to the Plan with the prior authorization request demonstrating that ALL of the following criteria are met (and after approval by a Plan Medical Director), with criteria specified below in items a through g: 
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Definitions
Adenomatous Polyp: An area where normal cells that line the inside of a person's colon begin to make mucous and form a mass on the inside of the intestinal tract.
Attenuated Familial Adenomatous Polyposis (AFAP):
Type of polyposis syndrome caused by an autosomal dominant trait that carries a high risk for the development of colorectal cancer. The condition is characterized by fewer adenomatous polyps in the colon and rectum than in classic familial adenomatous polyposis (FAP). AFAP is a variant (subtype)of FAP, but AFAP has fewer than 100 adenomatous colorectal polyps (with 30 being the average) and generally has a later age of onset than FAP (i.e., 55 years of age or older, although polyps may develop as early as the late teens). Both AFAP and FAP are associated with genetic mutations of the adenomatous polyposis coli or APC gene (normally a tumor suppressor gene) on chromosome 5q21. See the definition for familial adenomatous polyposis (FAP) included in this section.
Autosomal Dominant Trait:
Autosomal dominant inheritance means that the affected individual is genetically heterozygous (i.e., having dissimilar pairs of genes for any hereditary characteristic), such that each offspring of the affected individual has a 50% chance of inheriting the disease gene.
A single, abnormal gene on one of the first 22 non-sex chromosomes from either parent can cause an autosomal disorder. Dominant inheritance means an abnormal gene from one parent can cause disease, even though the matching gene from the other parent is normal. The abnormal gene dominates. Each child's risk is independent of whether their sibling has the disorder or not; children who do not inherit the abnormal gene will not develop or pass on the disease.
Autosomal Recessive Trait/Recessive Inheritance:
A gene mutation that must be inherited from both biological parents in order for an individual to be affected with the disease or trait. The individual has received two (2) copies the mutated gene (since genes come in pairs), one from each parent. Such parents are usually unaffected carriers because they only have a single copy of the abnormal gene. The individual who inherits two (2) copies of the same mutated gene is called a homozygote (i.e., a person who has two mutant forms of a particular gene which may result in a genetic disorder, one gene is inherited from each parent); in this case, the individual's parents, each with a single copy of the mutated gene, appear normal and are called gene carriers or heterozygotes (i.e., individuals who have two [2] different forms of a particular gene). The siblings of a patient with an autosomal recessive disease have, on average, a 25% chance of being affected with the same disease and a 50% chance of being carriers. 
BRAF Gene Mutation Testing of Colorectal
First-Degree Relative:
A blood relative of an individual who shares approximately 50% of the individual's genes defined as a biological parent, full sibling, or biological child.
Genetic Testing: According to U.S. Library of Medicine, genetic testing is defined as a type of medical test that identifies changes in chromosomes, genes, or proteins. The results of a genetic test can confirm or rule out a suspected genetic condition or help determine a person's chance of developing or passing on a genetic disorder. More than 1,000 genetic tests are currently in use, and more are being developed. Several methods can be used for genetic testing:
1. Molecular genetic tests (or gene tests) study single genes or short lengths of DNA to identify variations or mutations that lead to a genetic disorder.
2. Chromosomal genetic tests analyze whole chromosomes to see if there are large genetic changes, such as an extra copy of a chromosome or missing DNA, that cause a genetic condition.
3. Biochemical genetic tests study the amount or activity level of proteins; abnormalities in either can indicate changes to the DNA that result in a genetic disorder.
Hereditary Polyposis Syndrome/Hereditary Mixed Polyposis Syndrome:
A genetic condition that is associated with an increased risk of developing polyps (cancerous and/or noncancerous) in the digestive tract. Examples of hereditary polyposis syndromes that are associated with increased risk of hereditary colorectal cancer include attenuated familial adenomatous polyposis (AFAP), familial adenomatous polyposis (FAP), and MYH-associated polyposis (MAP).
Immunohistochemistry (IHC):
IHC testing uses special dyes to stain tissue samples. The presence or absence of staining indicates whether certain proteins are present in the tissue and identify which mutated genes caused the cancer. IHC is one of the two main initial tests performed on colorectal cancer tissue specimens to identify individuals who might have Lynch syndrome. Mismatch Repair (MMR) Mechanism: The DNA system controlled by certain genes that identifies, excises, and corrects errors in the pairing of the bases during DNA replication. MMR plays a key role in maintaining genomic stability. Mutations in the genes responsible for this mechanism can lead to certain genetic diseases and some forms of cancer.
Multigene Panel Tests:
Tests that evaluate more than one (1) gene simultaneously to detect changes in these genes' sequence and expression most commonly associated with certain diseases and other genes that may have limited evidence of an association to the disorder. Multigene panel tests may involve traditional exon-by-exon sequencing of targeted genes to identify genetic variants or use nextgeneration sequencing. Each laboratory establishes its own set of criteria for selecting the genes represented in a panel, even when panels are used for the same or similar clinical indications. The lack of regulatory oversight of genetic testing means that laboratories can change the components of a panel at any time, making it difficult to evaluate the clinical utility of multigene panel tests.
MutY Homolog (MUTYH)-Associated Polyposis (MAP):
A type of hereditary polyposis syndrome caused by an autosomal recessive trait that carries a high risk for the development of colorectal cancer. Individuals with MAP tend to develop multiple adenomatous colon polyps during their lifetime and are likely to develop polyps and colorectal cancer at a relatively young age, in their 20s to 50s. People with MAP most often resemble the clinical picture of attenuated familial adenomatous polyposis (AFAP), but it has been reported in individuals with clinical symptoms that are consistent with classical familial adenomatous polyposis (FAP) and Lynch syndrome. Individuals with MAP have mutations in both of their mutY homolog (MUTYH) genes (i.e., autosomal recessive trait, one from each biological parent), but patients often have no family history of colon cancer or polyps including their biological parents (although siblings may or may not be affected); therefore, genetic testing is used to identify at-risk individuals.
Next-Generation Sequencing (NGS or Massively Parallel Sequencing):
Genetic testing that involves sequencing of millions of DNA fragments using the following three (3) levels of molecular analysis: (1) Disease-targeted gene panels to sequence genes with an established role in the targeted disease, (2) exome sequencing of coding regions of the genome to include less common variants associated with the disease (i.e., a coding region is the segment of a gene that contains a protein-coding sequence called an exon in all 22,000 genes of the human genome); and (3) genome sequencing of both the coding and non-coding regions of the genome (i.e., the non-coding regions in between exons are called introns). Multiple sequencing platforms and different processes result in variability in test results among laboratories.
Prediction Model: Clinical model developed to provide quantitative estimate of the likelihood of a mismatch repair (MMR) mutation. These models each use different data and therefore provide a range of mutation-likelihood estimates for the same patient and can assist in the decision to undergo genetic testing. Data used in these models may include the following: patient gender, age at diagnosis of colorectal cancer (CRC), location of tumor, synchronous or metachronous CRC, family history and age at diagnosis for CRC and/or endometrial cancer, and/or and results of tumor testing for mismatch repair and previous germline testing. Examples of predictive models used for inherited colorectal cancer (CRC) include but are not limited to the following: MMRpredict model, MMRpro model, and PREMM5 model.
Proband:
The first affected individual in a family who is diagnosed with a genetic disorder, even if affected ancestors are known.
Second-Degree Relative:
A blood relative of an individual who shares approximately 25% of the individual's genes defined as a biological grandparent, grandchild, aunt, uncle, nephew, niece, or halfsibling.
Serrated Polyposis Syndrome:
Previously known as hyperplastic polyposis. A clinical diagnosis of serrated polyposis is considered in an individual who meets at least one (1) of the following empiric criteria: (1) at least 5 serrated polyps (which may include hyperplastic polyps, sessile serrated adenomas/polyps, and/or traditional serrated adenomas) proximal to the sigmoid colon with 2 or more of these being greater than 10 mm; (2) any number of serrated polyps proximal to the sigmoid colon in an individual who has a first-degree relative with serrated polyposis; and (3) greater than 20 serrated polyps of any size, but distributed throughout the colon (excluding polyps localized to the rectum and sigmoid unless those polyps are greater than 10 mm or serrations extend beyond widened base).
Occasionally, more than one affected case of serrated polyposis is seen in a family. Currently, no causative gene has been identified for serrated polyposis. The risk of colon cancer in this syndrome is elevated, although the precise risk remains to be defined. (Source: National Comprehensive Cancer Network.)
Sessile Serrated Polyp (Sessile Serrated Adenoma):
Polyp that displays a lumen with a serrated or stellate architecture. Serrated polyps may or may not be benign. The current classification of serrated lesions of the large intestine includes: hyperplastic polyps, traditional serrated adenomas, and sessile serrated adenomas or polyps with or without cytologic dysplasia.
Single Nucleotide Polymorphisms (SNPs):
The most common type of genetic variation among individuals. Each SNP represents a difference in a single DNA building block, called a nucleotide. SNPs occur normally throughout a person's DNA; normally these variations are found in the DNA between genes. If more than one (1) percent of a population does not carry the same nucleotide at a specific position in the DNA sequence, then this variation can be classified as a SNP. Most SNPs have no effect on health or development. When there is sufficient scientific evidence to support the clinical utility of testing, SNPs may help predict an individual's response to certain drugs, susceptibility to environmental factors, risk of developing particular diseases, and/or susceptibility to genetic diseases within families.
Third-Degree Relative:
A blood relative of an individual who shares 12.5% of the individual's genes as defined as a biological first cousin, great grandmother, or great grandfather.
Whole Exome Sequencing (WES)/Whole Genome Sequencing (WGS):
WES captures and sequences at a deep level the protein coding regions (called exons) of an individual's genes using first-generation sequencing techniques or next-generation sequencing to detect disease-causing variants and discover gene targets. While exons represent only 1% of the genome, they account for approximately 85% of disease-causing variants. Through identification of variants across the exome, WES avoids the need to run multiple single-gene tests, which require prior information about variants affecting the disease. WES has been performed in a number of cancers, whereby comparison between tumor DNA and normal DNA from the same individual allows identification of variants specific to the tumor, which may provide information used for diagnosis and treatment. WES is targeted sequencing of the subset of the human genome that contains functionally important sequences of protein-coding DNA, while whole genome sequencing (WGS) uses next-generation sequencing techniques to sequence both coding and non-coding regions of the genome. Because WES only evaluates the protein-coding regions of the human genome (exoms), WES is a more cost-effective alternative to WGS. WES produces a smaller, more manageable data set with faster turnaround time for analyses than WGS. WGS has the ability to detect structural variations located outside of the exome that may be related to many diseases and cannot be identified with WES. WES and WGS have been proposed to be more efficient than traditional sequencing methods in discovering the genetic causes of diseases, but there remain issues of error rates due to technical challenges and difficulty interpreting potential causative variants from variants of unknown significance generated for each patient. . Because the AMA, NCHS, and CMS may update codes more frequently or at different intervals than Plan policy updates, the list of applicable codes included in this Plan policy is for informational purposes only, may not be all inclusive, and is subject to change without prior notification. Whether a code is listed in the Applicable Coding section of this Plan policy does not constitute or imply member coverage or provider reimbursement. Providers are responsible for reporting all services using the most up-to-date industry-standard procedure and diagnosis codes as published by the AMA, NCHS, and CMS at the time of the service.
Providers are responsible for obtaining prior authorization for the services specified in the Medical Policy Statement section and Limitation section of this Plan policy, even if an applicable code appropriately describing the service that is the subject of this Plan policy is not included in the Applicable Coding section of this Plan policy. Coverage for services is subject to benefit eligibility under the member's benefit plan. Please refer to the member's benefits document in effect at the time of the service to determine coverage or non-coverage as it applies to an individual member. See Plan reimbursement policies for Plan billing guidelines.
Refer to the Plan's Genetic/Genomic Testing and Pharmacogenetics medical policy, policy number OCA 3.727, for additional guidelines regarding genetic testing. Plan prior authorization is required for all genetic testing, even when the applicable code for the genetic test is not listed in a Plan policy. Inheritance is a common factor in the pathogenesis of colon cancer with approximately one third of the cases exhibiting an inherited predisposition, while 3% to 5% of cases occur as part of one of the rare but highly penetrant inherited colon cancer syndromes. There are two (2) major types of inherited colorectal cancer: Colorectal cancer caused by hereditary polyposis syndromes and Lynch syndrome (also known as hereditary nonpolyposis colorectal cancer or HNPCC).
CPT Codes
Hereditary polyposis syndromes are thought to account for approximately 2% of all colon cancers and include attenuated familial adenomatous polyposis (AFAP), familial adenomatous polyposis (FAP), and MYH-associated polyposis (MAP). Familial adenomatous polyposis (FAP or classical familial adenomatous polyposis) is an autosomal dominant condition characterized by hundreds of polyps in the colon related to mutations of the adenomatous polyposis coli (APC) gene located on chromosome 5q21. Individuals with FAP have certain physical characteristics that can include congenital hypertrophy of retinal pigment epithelium (CHRPE), osteomas, odontomas, supernumerary teeth, epidermoid cysts, desmoids, and duodenal and other small bowel adenomas. The clinical diagnosis of classical FAP is based on the presence of over 100 adenomas or on the documentation of early onset adenomas in an individual with a family history of FAP. Patients with FAP are at risk for thyroid cancer usually occurring after age 30 years. Attenuated FAP or AFAP is a variant of FAP characterized by later onset of disease and fewer than 100 adenomas that typically occur in the right colon.
There is another more rare type of inherited colorectal cancer called MYH-associated polyposis or MAP. This type is a hereditary autosomal recessive colorectal cancer syndrome characterized by multiple adenomatous colon polyps. It is associated with mutations in the MUTYH gene, specifically Y165C and/or G382D. Individuals with MAP are at risk for developing colon cancer at young ages (30s and 40s). There may also be an increased risk of polyps in the small intestine. Often individuals with MAP will not have a family history of colon polyps or colon cancer because of the autosomal recessive pattern that indicates the genetic defect must be inherited from both parents. 
